Mayo Clinic Study introduces standardized definition for rapidly progressive dementia

UAE—Researchers at Mayo Clinic have developed a standardized, evidence-based definition for rapidly progressive dementia (RPD), a rare but severe form of cognitive decline that can develop within months rather than years.

The findings, published in the medical journal Neurology, are expected to improve early diagnosis, support faster treatment decisions, and create a common framework for future research into the condition.

Addressing a major diagnostic challenge

Unlike most forms of dementia, which typically worsen gradually over many years, RPD progresses at an alarming pace and can lead to severe disability or death within one to two years.

Although it accounts for only about 3% to 4% of dementia cases, physicians often struggle to diagnose the condition because its symptoms can arise from a wide range of underlying causes.

These include autoimmune disorders, infections, neurodegenerative diseases such as Alzheimer’s disease, and rare conditions like Creutzfeldt-Jakob disease.

According to Dr. Gregg Day, a behavioral neurologist at Mayo Clinic and the study’s senior author, clinicians have long needed a consistent way to identify patients whose cognitive decline is unusually rapid.

A standardized definition, he noted, can help healthcare providers recognize potentially treatable causes earlier while also laying the groundwork for large-scale research and future clinical trials.

The “1-in-1 or 2-in-2” Rule

To create a practical definition, the researchers relied on the Clinical Dementia Rating (CDR) scale, a widely used tool that measures dementia severity by assessing memory, orientation, judgment, problem-solving ability, daily activities, and personal care.

Under the new framework, a patient is considered to have rapidly progressive dementia if mild dementia develops within one year of symptom onset or if moderate-to-severe dementia develops within two years.

Researchers describe this approach as the “1-in-1 or 2-in-2” rule.

Because the criteria depend largely on clinical history rather than specialized testing, they can be applied in both advanced medical centers and healthcare facilities with limited resources.

Findings from more than 19,000 participants

The team evaluated the definition using two major datasets.

The first, known as the RaPID cohort, included 248 patients assessed for suspected RPD at Mayo Clinic and Washington University in St. Louis.

The second drew on data from the National Alzheimer’s Coordinating Center, which included more than 19,000 participants from 46 research centers across the United States.

Nearly 75% of patients in the RaPID cohort met the new criteria, and almost one-third had autoimmune or inflammatory conditions that may be reversible with appropriate treatment.

In the national dataset, approximately 4% met the definition, with Alzheimer’s disease emerging as the most common underlying cause.

Across both groups, patients classified as having RPD experienced cognitive decline three to four times faster than those with typical dementia.

Expanding research into dementia

The study comes as Mayo Clinic continues to expand its research efforts in dementia, Alzheimer’s disease, autoimmune encephalitis, and other neurological disorders.

 Researchers believe the new definition will help identify patients earlier in the disease course and improve collaboration among research centers investigating the biological factors that drive unusually rapid cognitive decline.

The newly proposed criteria also provide a consistent standard that can be used across hospitals, outpatient clinics, and research institutions, helping clinicians and scientists evaluate patients using the same diagnostic framework.